China-based micro/nano technology developer HICOMP MicroTech (Suzhou) Co., Ltd has raised RMB 100 million (USD 13.9 million) in a Series B+ financing round. The round was led by Shunwei Capital, with contributions from IC Space’s industrial investment platform. The proceeds will be used to support microfluidics research and development (R&D), manufacturing contract implementation, product pipeline expansion, key technology R&D, and market development both domestically and internationally.
Company Background and Offerings
Founded in 2014, HICOMP provides customized life science laboratory products and microfluidic (lab on a chip) solutions to the global market. The company’s offerings cover a wide range of application fields, including immunodiagnosis, biochemical diagnosis, blood detection, PCR detection, gene sequencing, liquid biopsy, organ chip, drug delivery, life science research, animal diagnosis, environmental protection, food safety, and biosafety. Specific products and services include microfluidic chips, customized kits, laboratory consumables, microfluidic R&D technology services, and contract development and manufacturing organization (CDMO) services.
Future Outlook
The Series B+ financing round underscores HICOMP MicroTech’s commitment to advancing its micro/nano technology platform. By leveraging the new funds, the company aims to enhance its R&D capabilities, expand its product portfolio, and strengthen its market presence globally, particularly in the microfluidics sector.-Fineline Info & Tech
